Kiniksa Pharmaceuticals International, plc KNSA Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's retained earnings?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported retained earnings of -$439.55M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's retained earnings changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's retained earnings increased by 14.3% year-over-year, from -$512.6M to -$439.55M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's retained earnings?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's retained earnings has grown at a -2.2% compound annual growth rate (CAGR), from -$517.47M to -$462.14M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.